Abstract
The pharmacokinetic characteristics of cenobamate are described and the interaction effects of concomitant antiseizure medications on cenobamate in terms of its pharmacokinetics and pharmacodynamics are highlighted.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Summary of product characteristics: Cenobamate (XCopri). SK Life Science Inc. Last update Aug 2020.
Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Perucca P, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the fifteenth EILAT conference on new antiepileptic drugs and devices (EILAT XV). II. Drugs in more advanced clinical development. Epilepsia. 2020;61:2365–85.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Patsalos, P.N. (2022). Cenobamate. In: Antiseizure Medication Interactions. Springer, Cham. https://doi.org/10.1007/978-3-030-82790-8_6
Download citation
DOI: https://doi.org/10.1007/978-3-030-82790-8_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-82789-2
Online ISBN: 978-3-030-82790-8
eBook Packages: MedicineMedicine (R0)